Anavex Life Sciences Announces $50 Million Registered Direct Offering

Anavex Life Sciences Announces $50 Million Registered Direct Offering NEW YORK – June 22, 2021 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders,…